CEL-SCI Corp
$ 4.38
0.46%
15 Apr - close price
- Market Cap 36,876,700 USD
- Current Price $ 4.38
- High / Low $ 4.45 / 4.14
- Stock P/E N/A
- Book Value 1.38
- EPS -3.70
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.60 %
- ROE -2.12 %
- 52 Week High 13.48
- 52 Week Low 1.98
About
CEL-SCI Corporation is dedicated to the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia.
Analyst Target Price
$25.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-17 | 2025-12-23 | 2025-08-12 | 2025-05-13 | 2025-01-13 | 2024-12-31 | 2024-08-14 | 2024-05-15 | 2024-02-14 | 2023-12-21 | 2023-08-10 | 2023-05-12 |
| Reported EPS | -0.68 | -0.86 | -1.36 | -2.3323 | -2.7 | -2.7003 | -0.14 | -0.14 | -0.14 | -0.16 | -0.19 | -0.19 |
| Estimated EPS | 0 | None | None | None | -3.3 | -0.1 | -0.13 | -0.14 | -0.14 | -0.16 | -0.16 | -0.17 |
| Surprise | -0.68 | 0 | 0 | 0 | 0.6 | -2.6003 | -0.01 | 0 | 0 | 0 | -0.03 | -0.02 |
| Surprise Percentage | None% | None% | None% | None% | 18.1818% | -2600.3% | -7.6923% | 0% | 0% | 0% | -18.75% | -11.7647% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CVM
2026-04-01 15:10:40
CEL SCI CEO Geert R. Kersten was awarded 1,682 shares of common stock on March 31, 2026, valued at $3.21 per share. This stock grant increased his direct holdings to 122,497 common shares. The transaction, reported in a Form 4 SEC filing, represents an equity-based compensation rather than an open-market purchase.
2026-04-01 15:10:40
CEL-SCI Corp's Chief Financial Officer, Patricia B. Prichep, was granted 1,336 shares of Common Stock on March 31, 2026, as reported in a Form 4 filing. This equity award, valued at $3.21 per share, increases her direct holdings to 13,364 shares and is considered a routine compensation-related transaction. The filing provides transparent details about insider trading activity for investors.
2026-04-01 11:09:40
CEL SCI CORP's Chief Scientific Officer, Talor Eyal, acquired 747 shares of Common Stock on March 31, 2026, through a grant or award. The acquisition was valued at $3.21 per share, increasing Eyal's direct holdings to 7,011 shares. This transaction was reported in a Form 4 filing with the SEC, indicating a neutral impact and sentiment.
2026-04-01 09:10:40
This article provides a technical analysis of CEL-SCI Corp (CVM) as of April 1, 2026, indicating an overall "Sell" consensus based on various technical indicators. It details momentum indicators like RSI and MACD, support and resistance levels, and analyzes the stock's performance relative to its moving averages. The analysis suggests that CVM is currently in neutral RSI territory but shows strong "Sell" signals from MACD and its position below key moving averages.
2026-03-23 13:10:30
This article analyzes the historical performance of a $1,000 investment in CEL-SCI Corp (CVM) over various periods, showing significant losses over the last five and ten years, while briefly detailing the company's focus on cancer immunotherapy and its lead product, Multikine. It also highlights CEL-SCI's ongoing regulatory efforts in the U.S. and Saudi Arabia and its financial status as a clinical-stage biotechnology company.
2026-02-21 16:11:01
Cel-Sci Corporation CEO Kersten Geert R. recently purchased 38,023 shares of common stock for $200,000, increasing his direct ownership to 120,815 shares. Additionally, Cel-Sci's Board of Directors approved revisions to the company's Shareholder Rights Agreement, as disclosed in an SEC filing, indicating ongoing corporate governance efforts. These developments reflect strategic management initiatives for the NYSE American-listed company.
